DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
43.79 USD
+0.05 (+0.11%)
43.79 USD
0 (0%)
Taking everything into account, DOCS scores 7 out of 10 in our fundamental rating. DOCS was compared to 35 industry peers in the Health Care Technology industry. DOCS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. DOCS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make DOCS a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS has a better Return On Assets (20.13%) than 100.00% of its industry peers.
The Return On Equity of DOCS (23.10%) is better than 100.00% of its industry peers.
The Return On Invested Capital of DOCS (18.16%) is better than 100.00% of its industry peers.
DOCS had an Average Return On Invested Capital over the past 3 years of 14.17%. This is significantly above the industry average of 6.61%.
The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
DOCS's Profit Margin of 40.72% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 39.72%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Operating Margin has improved in the last couple of years.
DOCS's Gross Margin of 90.20% is amongst the best of the industry. DOCS outperforms 97.14% of its industry peers.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), DOCS is creating value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DOCS has an Altman-Z score of 32.84. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 32.84, DOCS belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 32.84 |
ROIC/WACC1.88
WACC9.68%
2.3 Liquidity
DOCS has a Current Ratio of 7.79. This indicates that DOCS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.79, DOCS belongs to the top of the industry, outperforming 91.43% of the companies in the same industry.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
DOCS's Quick ratio of 7.79 is amongst the best of the industry. DOCS outperforms 91.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.43%, which is quite impressive.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 79.21% on average per year.
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
The Revenue has been growing by 37.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.75% on average per year.
The Revenue is expected to grow by 11.49% on average over the next years. This is quite good.
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 26.70, the valuation of DOCS can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 80.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.19, DOCS is valued at the same level.
Based on the Price/Forward Earnings ratio of 25.00, the valuation of DOCS can be described as rather expensive.
Based on the Price/Forward Earnings ratio, DOCS is valued a bit cheaper than the industry average as 68.57% of the companies are valued more expensively.
DOCS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.7 | ||
| Fwd PE | 25 |
4.2 Price Multiples
DOCS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 62.86% of the companies in the same industry.
DOCS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 74.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.42 | ||
| EV/EBITDA | 25.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)1.88
PEG (5Y)0.34
EPS Next 2Y11.46%
EPS Next 3Y11.79%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.79
+0.05 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners91.38%
Inst Owner Change-0.02%
Ins Owners1.96%
Ins Owner Change0.19%
Market Cap8.24B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts77.86
Price Target69.67 (59.1%)
Short Float %5.99%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)-0.18%
PT rev (3m)-1.81%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0.18%
EPS NY rev (3m)4.31%
Revenue NQ rev (1m)0.06%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)1.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.7 | ||
| Fwd PE | 25 | ||
| P/S | 13.27 | ||
| P/FCF | 26.42 | ||
| P/OCF | 25.79 | ||
| P/B | 7.53 | ||
| P/tB | 8.49 | ||
| EV/EBITDA | 25.75 |
EPS(TTM)1.64
EY3.75%
EPS(NY)1.75
Fwd EY4%
FCF(TTM)1.66
FCFY3.79%
OCF(TTM)1.7
OCFY3.88%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)1.88
PEG (5Y)0.34
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 32.84 |
F-Score9
WACC9.68%
ROIC/WACC1.88
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y14.22%
EPS Next 2Y11.46%
EPS Next 3Y11.79%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year14.06%
Revenue Next 2Y12.55%
Revenue Next 3Y12.02%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year17.72%
EBIT Next 3Y13.76%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
What is the valuation status for DOCS stock?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What are the PE and PB ratios of DOXIMITY INC-CLASS A (DOCS) stock?
The Price/Earnings (PE) ratio for DOXIMITY INC-CLASS A (DOCS) is 26.7 and the Price/Book (PB) ratio is 7.53.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 14.22% in the next year.